{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T00:38:31Z","timestamp":1795221511790,"version":"4.10.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA266857"],"award-info":[{"award-number":["R01CA266857"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA266857"],"award-info":[{"award-number":["R01CA266857"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Department of Health & Human Services | U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["R01FD007268"],"award-info":[{"award-number":["R01FD007268"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Biomed. Eng"],"DOI":"10.1038\/s41551-025-01380-1","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T09:02:21Z","timestamp":1752829341000},"page":"1437-1452","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Sensitization of tumours to immunotherapy by boosting early type-I interferon responses enables epitope spreading"],"prefix":"10.1038","volume":"9","author":[{"given":"Sadeem","family":"Qdaisat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Wummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian D.","family":"Stover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingpeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"McGuiness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Weidert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Chardon-Robles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Grippin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"DeVries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiano","family":"Marconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Karachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Jobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2787-4317","authenticated-orcid":false,"given":"Rachel S. F.","family":"Moor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"von Roemeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3204-7279","authenticated-orcid":false,"given":"Duy T.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3616-849X","authenticated-orcid":false,"given":"Leighton","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagheme","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnav","family":"Barpujari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary","family":"Geffrard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yodarlynis","family":"Campaneria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Ogando-Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathleen","family":"Rabideau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruvkumar","family":"Soni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6345-5921","authenticated-orcid":false,"given":"Sheila","family":"Carrera-Justiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristianna","family":"Fredenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie L.","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4461-7227","authenticated-orcid":false,"given":"W. Gregory","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5513-1233","authenticated-orcid":false,"given":"John A.","family":"Ligon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine T.","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6420-5150","authenticated-orcid":false,"given":"Ji-Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duane A.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7493-5365","authenticated-orcid":false,"given":"Hector R.","family":"Mendez-Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5309-3197","authenticated-orcid":false,"given":"Elias J.","family":"Sayour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"1380_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi, S., Yuan, R. & Engleman, E. G. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu. Rev. Pathol. 16, 223\u2013249 (2021).","journal-title":"Annu. Rev. Pathol."},{"key":"1380_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56\u201361 (2015).","journal-title":"Science"},{"key":"1380_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000213","volume":"2","author":"C Granier","year":"2017","unstructured":"Granier, C. et al. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open 2, e000213 (2017).","journal-title":"ESMO Open"},{"key":"1380_CR4","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8, 1069\u20131086 (2018).","journal-title":"Cancer Discov."},{"key":"1380_CR5","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s40425-018-0442-7","volume":"6","author":"V Verma","year":"2018","unstructured":"Verma, V. et al. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J. Immunother. Cancer 6, 128 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"1380_CR6","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1093\/annonc\/mdx213","volume":"28","author":"A Chauhan","year":"2017","unstructured":"Chauhan, A., Burkeen, G., Houranieh, J., Arnold, S. & Anthony, L. Immune checkpoint-associated cardiotoxicity: case report with systematic review of literature. Ann. Oncol. 28, 2034\u20132038 (2017).","journal-title":"Ann. Oncol."},{"key":"1380_CR7","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189\u20132199 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1380_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa1348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science https:\/\/doi.org\/10.1126\/science.aaa1348 (2015).","journal-title":"Science"},{"key":"1380_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature12634","volume":"502","author":"C Kandoth","year":"2013","unstructured":"Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333\u2013339 (2013).","journal-title":"Nature"},{"key":"1380_CR10","doi-asserted-by":"crossref","unstructured":"Fares, C. M., Van Allen, E. M., Drake, C. G., Allison, J. P. & Hu-Lieskovan, S. Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients? Am. Soc. Clin. Oncol. Educ. Book 39, 147\u2013164 (2019).","DOI":"10.1200\/EDBK_240837"},{"key":"1380_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","volume":"118","author":"RW Jenkins","year":"2018","unstructured":"Jenkins, R. W., Barbie, D. A. & Flaherty, K. T. Mechanisms of resistance to immune checkpoint inhibitors. Br. J. Cancer 118, 9\u201316 (2018).","journal-title":"Br. J. Cancer"},{"key":"1380_CR12","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad, G., Helmink, B. A., Sharma, P. & Wargo, J. A. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 184, 5309\u20135337 (2021).","journal-title":"Cell"},{"key":"1380_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.it.2012.10.004","volume":"34","author":"MB Fuertes","year":"2013","unstructured":"Fuertes, M. B., Woo, S. R., Burnett, B., Fu, Y. X. & Gajewski, T. F. Type I interferon response and innate immune sensing of cancer. Trends Immunol. 34, 67\u201373 (2013).","journal-title":"Trends Immunol."},{"key":"1380_CR14","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","volume":"167","author":"JL Benci","year":"2016","unstructured":"Benci, J. L. et al. Tumour interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell 167, 1540\u20131554.e12 (2016).","journal-title":"Cell"},{"key":"1380_CR15","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1158\/0008-5472.CAN-15-3142","volume":"77","author":"X Wang","year":"2017","unstructured":"Wang, X. et al. Suppression of type I IFN signaling in tumours mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy. Cancer Res. 77, 839\u2013850 (2017).","journal-title":"Cancer Res."},{"key":"1380_CR16","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/s41422-019-0224-x","volume":"29","author":"N Jacquelot","year":"2019","unstructured":"Jacquelot, N. et al. Sustained type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Res. 29, 846\u2013861 (2019).","journal-title":"Cell Res."},{"key":"1380_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/adbi.201900237","volume":"4","author":"L Zhou","year":"2020","unstructured":"Zhou, L. et al. A dual role of type I interferons in antitumour immunity. Adv. Biosyst. 4, e1900237 (2020).","journal-title":"Adv. Biosyst."},{"key":"1380_CR18","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1084\/jem.20101158","volume":"208","author":"MS Diamond","year":"2011","unstructured":"Diamond, M. S. et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumours. J. Exp. Med. 208, 1989\u20132003 (2011).","journal-title":"J. Exp. Med."},{"key":"1380_CR19","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1084\/jem.20101159","volume":"208","author":"MB Fuertes","year":"2011","unstructured":"Fuertes, M. B. et al. Host type I IFN signals are required for antitumour CD8+ T cell responses through CD8\u03b1+ dendritic cells. J. Exp. Med. 208, 2005\u20132016 (2011).","journal-title":"J. Exp. Med."},{"key":"1380_CR20","doi-asserted-by":"publisher","first-page":"6195","DOI":"10.1021\/acs.nanolett.8b02179","volume":"18","author":"EJ Sayour","year":"2018","unstructured":"Sayour, E. J. et al. Personalized tumour RNA loaded lipid-nanoparticles prime the systemic and intratumoural milieu for response to cancer immunotherapy. Nano Lett. 18, 6195\u20136206 (2018).","journal-title":"Nano Lett."},{"key":"1380_CR21","doi-asserted-by":"publisher","first-page":"e1256527","DOI":"10.1080\/2162402X.2016.1256527","volume":"6","author":"EJ Sayour","year":"2016","unstructured":"Sayour, E. J. et al. Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles. Oncoimmunology 6, e1256527 (2016).","journal-title":"Oncoimmunology"},{"key":"1380_CR22","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","volume":"23","author":"K Kariko","year":"2005","unstructured":"Kariko, K., Buckstein, M., Ni, H. & Weissman, D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165\u2013175 (2005).","journal-title":"Immunity"},{"key":"1380_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-07851-z","volume":"7","author":"VP Baklaushev","year":"2017","unstructured":"Baklaushev, V. P. et al. Luciferase expression allows bioluminescence imaging but imposes limitations on the orthotopic mouse (4T1) model of breast cancer. Sci. Rep. 7, 7715 (2017).","journal-title":"Sci. Rep."},{"key":"1380_CR24","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1016\/j.cell.2024.04.003","volume":"187","author":"HR Mendez-Gomez","year":"2024","unstructured":"Mendez-Gomez, H. R. et al. RNA aggregates harness the danger response for potent cancer immunotherapy. Cell 187, 2521\u20132535.e1 (2024).","journal-title":"Cell"},{"key":"1380_CR25","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s12015-016-9670-8","volume":"12","author":"AM Ansari","year":"2016","unstructured":"Ansari, A. M. et al. Cellular GFP toxicity and immunogenicity: potential confounders in in vivo cell tracking experiments. Stem Cell Rev. Rep. 12, 553\u2013559 (2016).","journal-title":"Stem Cell Rev. Rep."},{"key":"1380_CR26","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/imcb.12636","volume":"101","author":"C Poloni","year":"2023","unstructured":"Poloni, C. et al. T-cell activation-induced marker assays in health and disease. Immunol. Cell Biol. 101, 491\u2013503 (2023).","journal-title":"Immunol. Cell Biol."},{"key":"1380_CR27","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1200\/JCO.18.00149","volume":"37","author":"M Reck","year":"2019","unstructured":"Reck, M. et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or greater. J. Clin. Oncol. 37, 537\u2013546 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1380_CR28","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein, R. M. et al. Tumour mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51, 202\u2013206 (2019).","journal-title":"Nat. Genet."},{"key":"1380_CR29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","volume":"5","author":"NJ Llosa","year":"2015","unstructured":"Llosa, N. J. et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 5, 43\u201351 (2015).","journal-title":"Cancer Discov."},{"key":"1380_CR30","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1001\/jamaoncol.2020.7684","volume":"7","author":"C Valero","year":"2021","unstructured":"Valero, C. et al. Response rates to anti-PD-1 immunotherapy in microsatellite-stable solid tumours with 10 or more mutations per megabase. JAMA Oncol. 7, 739\u2013743 (2021).","journal-title":"JAMA Oncol."},{"key":"1380_CR31","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1126\/science.1164206","volume":"322","author":"K Hildner","year":"2008","unstructured":"Hildner, K. et al. Batf3 deficiency reveals a critical role for CD8\u03b1+ dendritic cells in cytotoxic T cell immunity. Science 322, 1097\u20131100 (2008).","journal-title":"Science"},{"key":"1380_CR32","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","volume":"41","author":"SR Woo","year":"2014","unstructured":"Woo, S. R. et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumours. Immunity 41, 830\u2013842 (2014).","journal-title":"Immunity"},{"key":"1380_CR33","doi-asserted-by":"publisher","first-page":"310","DOI":"10.4049\/jimmunol.1501836","volume":"196","author":"JJ Suschak","year":"2016","unstructured":"Suschak, J. J., Wang, S., Fitzgerald, K. A. & Lu, S. A cGAS-independent STING\/IRF7 pathway mediates the immunogenicity of DNA vaccines. J. Immunol. 196, 310\u2013316 (2016).","journal-title":"J. Immunol."},{"key":"1380_CR34","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930\u20132940 (2017).","journal-title":"J. Clin. Invest."},{"key":"1380_CR35","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/neuonc\/noz015","volume":"21","author":"A Karachi","year":"2019","unstructured":"Karachi, A. et al. Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition. Neuro Oncol. 21, 730\u2013741 (2019).","journal-title":"Neuro Oncol."},{"key":"1380_CR36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/00002371-199701000-00002","volume":"20","author":"Y Zhai","year":"1997","unstructured":"Zhai, Y. et al. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J. Immunother. 20, 15\u201325 (1997).","journal-title":"J. Immunother."},{"key":"1380_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.726656","volume":"9","author":"C Zhang","year":"2021","unstructured":"Zhang, C. et al. Identification of Claudin-6 as a molecular biomarker in pan-cancer through multiple omics integrative analysis. Front. Cell Dev. Biol. 9, 726656 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"1380_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-5-20","volume":"5","author":"M Mansour","year":"2007","unstructured":"Mansour, M. et al. Therapy of established B16-F10 melanoma tumours by a single vaccination of CTL\/T helper peptides in VacciMax. J. Transl. Med. 5, 20 (2007).","journal-title":"J. Transl. Med."},{"key":"1380_CR39","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1093\/jnci\/88.22.1635","volume":"88","author":"SA Rosenberg","year":"1996","unstructured":"Rosenberg, S. A. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J. Natl Cancer Inst. 88, 1635\u20131644 (1996).","journal-title":"J. Natl Cancer Inst."},{"key":"1380_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/0471142735.im2001s39","author":"WW Overwijk","year":"2001","unstructured":"Overwijk, W. W. & Restifo, N. P. B16 as a mouse model for human melanoma. Curr. Protoc. Immunol. https:\/\/doi.org\/10.1002\/0471142735.im2001s39 (2001).","journal-title":"Curr. Protoc. Immunol."},{"key":"1380_CR41","doi-asserted-by":"publisher","unstructured":"Balmas, E. et al. Islet-autoreactive CD4+ T cells are linked with response to alefacept in type 1 diabetes. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.167881 (2023).","DOI":"10.1172\/jci.insight.167881"}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01380-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01380-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01380-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T22:02:05Z","timestamp":1758146525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01380-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":41,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["1380"],"URL":"https:\/\/doi.org\/10.1038\/s41551-025-01380-1","relation":{},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"assertion":[{"value":"17 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.A.M. and C.T.F. hold an ownership interest in iOncologi, Inc. W.G.S. holds interest in Aurita, Inc. E.J.S. is a paid consultant for Siren Biotechnology and serves on the external advisory board of Nature\u2019s Toolbox with stock options. The paper discusses pending patent applications from S.Q., J.M., A.G., W.G.S., M.R., D.A.M., P.C., H.R.M.-G. and E.J.S, some of which are licensed to iOncologi, Inc. H.R.M.-G. and E.J.S. receive royalty payments from iOncologi, Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}